Clinical utilization of teh cell free DNA as tumor biomarker.

2014 Fiscal Year Final Research Report

• Project/Area Number: 24300337
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Tumor diagnosis
• Research Institution: The University of Tokyo
• Principal Investigator: EIJI SUNAMI 東京大学, 医学部附属病院, 講師 (70345205)
• Co-Investigator(Kenkyū-buntansha): TSUNO Hirokazu 東京大学, 医学部附属病院, 講師 (50282637) ; KAWAI Kazushige 東京大学, 医学部附属病院, 助教 (80571942)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: 大腸がん / バイオマーカー / 血中遊離DNA / LINE1

Outline of Final Research Achievements

Circulating Cell-free DNA (cfDNA) is known to be increased in multiple cancers reflecting necrosis and apoptosis of tumor tissue and is target for various genetic analysis. The global hypomethylation is thought to correlate with genomic instability and tumor progression. In this study, we quantified the global methylation status of cfDNA in plasma extracted from colorectal cancer (CRC) patients, and investigated its clinical usefulness as a biomarker.LINE-1 hypomethylation index (LHI) in plasma may have a potential to serve as a biomarker enabling us to detect CRC patient at early stage.

Free Research Field

大腸がん